Elutia develops proprietary drug-eluting biomatrix (DEB) products that combine biological scaffolds with localized drug delivery to improve surgical outcomes and reduce complications such as infection, rejection, and fibrosis. The company markets SimpliDerm, a human acellular dermal matrix for soft tissue and breast reconstruction in women's health, and a portfolio of porcine small intestinal submucosa-derived cardiovascular products (ProxiCor, Tyke, and VasCure) for cardiac and vascular repair, with lead pipeline candidates NXT-41 and NXT-41x representing next-generation biomatrices designed for reconstructive surgery. Elutia sells primarily through independent sales agents in the United States and generates revenue from product sales while sourcing materials from specialized suppliers; the company competes against established medical device manufacturers by differentiating through its integrated biologic-drug combination platform and focus on high-complication surgical procedures with significant unmet medical needs.